It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Rapid expansion of the pulmonary microvasculature through angiogenesis drives alveolarization, the final stage of lung development that occurs postnatally and dramatically increases lung gas-exchange surface area. Disruption of pulmonary angiogenesis induces long-term structural and physiologic lung abnormalities, including bronchopulmonary dysplasia, a disease characterized by compromised alveolarization. Although endothelial cells are primary determinants of pulmonary angiogenesis, mesenchymal cells (MC) play a critical and dual role in angiogenesis and alveolarization. Therefore, we performed single cell transcriptomics and in-situ imaging of the developing lung to profile mesenchymal cells during alveolarization and in the context of lung injury. Specific mesenchymal cell subtypes were present at birth with increasing diversity during alveolarization even while expressing a distinct transcriptomic profile from more mature correlates. Hyperoxia arrested the transcriptomic progression of the MC, revealed differential cell subtype vulnerability with pericytes and myofibroblasts most affected, altered cell to cell communication, and led to the emergence of Acta1 expressing cells. These insights hold the promise of targeted treatment for neonatal lung disease, which remains a major cause of infant morbidity and mortality across the world.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of New South Wales, School of Clinical Medicine, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432); University of New South Wales, Cellular Genomics Futures Institute, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432); University of New South Wales, Evolution & Ecology Research Centre, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432)
2 Stanford University School of Medicine, Center for Excellence in Pulmonary Biology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University School of Medicine, Division of Pulmonary, Asthma and Sleep Medicine, Department of Pediatrics, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
3 Stanford University School of Medicine, Center for Excellence in Pulmonary Biology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University School of Medicine, Division of Critical Care Medicine, Department of Pediatrics, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
4 Trinity College Dublin, School of Biochemistry and Immunology, Dublin, Ireland (GRID:grid.8217.c) (ISNI:0000 0004 1936 9705)
5 University of New South Wales, School of Clinical Medicine, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432)
6 Stanford University, Department of Bioengineering, Stanford, USA (GRID:grid.168010.e) (ISNI:0000 0004 1936 8956)
7 Stanford University, Department of Bioengineering, Stanford, USA (GRID:grid.168010.e) (ISNI:0000 0004 1936 8956); Chan Zuckerberg Biohub, San Francisco, USA (GRID:grid.499295.a) (ISNI:0000 0004 9234 0175); Stanford University, Department of Applied Physics, Stanford, USA (GRID:grid.168010.e) (ISNI:0000 0004 1936 8956)
8 Stanford University School of Medicine, Center for Excellence in Pulmonary Biology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University School of Medicine, Division of Pulmonary, Asthma and Sleep Medicine, Department of Pediatrics, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Chan Zuckerberg Biohub, San Francisco, USA (GRID:grid.499295.a) (ISNI:0000 0004 9234 0175)